[Therapy of peritonitis in continuing ambulatory peritoneal dialysis].
D002512:Cephalothin / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000378:metabolism; D006801:Humans; D010423:Pentazocine / Q000627:therapeutic use; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy*; D011343:Procaine / Q000627:therapeutic use; D013997:Time Factors; D014031:Tobramycin / Q000627:therapeutic use
D011343:Procaine; D006493:Heparin; D002512:Cephalothin; D010423:Pentazocine; D014031:Tobramycin
Therapie der Peritonitis bei kontinuierlicher ambulanter Peritonealdialyse.